Lung Cancer

Evidence supports SABR as standard of care for inoperable NSCLC

Stereotactic ablative radiotherapy (SABR) should be the treatment of choice for patients with inoperable peripherally located stage 1 non-small cell lung cancer (NSCLC), say the Australian authors of a phase 3 trial published in Lancet Oncology. The randomised CHISEL trial conducted across 14 hospitals in Australia and New Zealand randomly assigned 101 patients with peripherally ...

Already a member?

Login to keep reading.

© 2022 the limbic